January 13 () – Investment bank Biogen Inc. is working with Goldman Sachs to find potential targets for the acquisition, Stat News reported Thursday, citing an unnamed source.
The report said the company’s management had warmed up to the idea of acquiring the controversial Alzheimer’s drug in the wake of the unrest over Aduhelm.
Biogen did not immediately respond to a request for comment on the report.
On Tuesday, the U.S. Centers for Medicaid and Medicare Services (CMS) said it would cover Aduhelm and similar treatments only for patients registered in approved clinical trials, and threatened to sell the drug.
In a conference call with analysts on Thursday, Biogen CEO Michel Vounatsos said he was working with the board on “tactical, short-term measures, but also strategic options.”
Vounatsos answered the question of whether the company would consider any strategic options to protect shareholder value, especially in light of the Aduhelm dispute.
Aduhelm was confirmed by the U.S. Food and Drug Administration in June despite the agency’s external advisors claiming that the clinical benefits of the treatment had not been proven.
Leroy Leon’s interview; Edited by Devika Syamnat